Xeris CEO Sees Recorlev Reaching $1B in Annual Sales Earlier Than Expected
CEO John Shannon said Recorlev could generate $1 billion in annual sales three to four years earlier than expected. Xeris shares surged more than 16% in premarket trading Thursday.
Shares of Xeris Biopharma (XERS) surged more than 16% in premarket trading on Thursday, marking its best day in over a year, after CEO John Shannon said its lead drug to treat Cushing’s Syndrome could generate $1 billion in annual sales three to four years earlier than expected.If the levels hold a…